Bristol-Myers Squibb Company (NYSE:BMY) added 0.14% and closed its last session at $56.44. The stock has the market capitalization of $94.32 Billion with the total outstanding shares of 1.67 Billion. Bristol-Myers Squibb Company. has Analysts’ Mean Recommendation of 2.5 between the scale of 1 to 5 (1 represents Strong Buy and 5 means Sell). The stock currently has P/E of 28.11 for trailing twelve months while its Forward P/E is 18.96.

Bristol-Myers Squibb Company (NYSE:BMY) touched its 52-Week High of $77.12 on Jul 15, 2016 while it’s 52-Week Low of $49.03 on Oct 25, 2016. The company currently has Return on Assets of 10.3 percent, Return on Equity of 22.7% and Return on Investment of 4.6 percent. The stock currently showing Weekly Volatility of 1.28%% and Monthly Volatility of 1.72% Percent with Average True Range of 1.02 and Beta of 0.94.

The 23 analysts offering 12-month price forecasts for Bristol-Myers Squibb have a median target of 61.00, with a high estimate of 100.00 and a low estimate of 44.20. The median estimate represents a +8.08% increase from the last price of 56.44.

Press Release:

The Company on 30 November reported it will take part in the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016, in New York. Giovanni Caforio, M.D., chief executive officer, and Francis Cuss, MB, BChir, FRCP, chief scientific officer, will make formal remarks and answer questions about the company at 8:00 a.m. EST.

Company Profile:

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.